MX2016004580A - Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. - Google Patents

Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.

Info

Publication number
MX2016004580A
MX2016004580A MX2016004580A MX2016004580A MX2016004580A MX 2016004580 A MX2016004580 A MX 2016004580A MX 2016004580 A MX2016004580 A MX 2016004580A MX 2016004580 A MX2016004580 A MX 2016004580A MX 2016004580 A MX2016004580 A MX 2016004580A
Authority
MX
Mexico
Prior art keywords
pcsk9 inhibitor
treat hyperlipidemia
pcsk9
present
inhibitor
Prior art date
Application number
MX2016004580A
Other languages
English (en)
Inventor
J Sasiela William
C Pordy Robert
BACCARA-DINET Marie
Bessac Laurence
Chaudhari Umesh
Hanotin Corinne
A Schwemmer Gipe Daniel
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2016004580A publication Critical patent/MX2016004580A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invención proporciona métodos para tratar la hiperlipidemia en pacientes que no están recibiendo una terapia de estatinas. Los métodos de la presente invención comprenden administrar a un paciente una composición farmacéutica que comprende un inhibidor de PCSK9. En determinadas realizaciones, el inhibidor de PCSK9 es un anticuerpo anti-PCSK9 tal como el anticuerpo ilustrativo denominado en la presente memoria mAb316P.
MX2016004580A 2013-10-11 2014-10-10 Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. MX2016004580A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US201462025104P 2014-07-16 2014-07-16
EP14306221 2014-07-31
US201462054571P 2014-09-24 2014-09-24
EP14306584 2014-10-09
PCT/US2014/060109 WO2015054619A2 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia

Publications (1)

Publication Number Publication Date
MX2016004580A true MX2016004580A (es) 2016-12-08

Family

ID=52813751

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016004580A MX2016004580A (es) 2013-10-11 2014-10-10 Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2020004023A MX2020004023A (es) 2013-10-11 2016-04-08 Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2022013172A MX2022013172A (es) 2013-10-11 2016-04-08 Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020004023A MX2020004023A (es) 2013-10-11 2016-04-08 Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2022013172A MX2022013172A (es) 2013-10-11 2016-04-08 Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.

Country Status (14)

Country Link
US (1) US20150140002A1 (es)
EP (2) EP3055333B1 (es)
JP (2) JP6846931B2 (es)
KR (3) KR20220048051A (es)
CN (3) CN105814085A (es)
AU (2) AU2014331754B2 (es)
CA (1) CA2926942A1 (es)
EA (1) EA037526B1 (es)
ES (1) ES2914978T3 (es)
IL (1) IL244995B (es)
MX (3) MX2016004580A (es)
PL (2) PL3055333T4 (es)
TW (1) TWI669131B (es)
WO (1) WO2015054619A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
AU2012210480B2 (en) 2011-01-28 2017-05-18 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
KR101964031B1 (ko) 2011-09-16 2019-04-02 리제너론 파아마슈티컬스, 인크. 전구단백질 전환효소 서브틸리신 켁신-9 (ＰＣＳＫ9)의 억제제를 투여함으로써 지질단백질(ａ)의 농도를 낮추는 방법
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
MX2015016887A (es) 2013-06-07 2016-07-26 Regeneron Pharma Metodos para inhibir la aterosclerosis mediante la administracion de un inhibidor de pcsk9.
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
RU2735521C2 (ru) 2014-07-16 2020-11-03 Санофи Байотекнолоджи Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
US20180140747A1 (en) * 2015-04-15 2018-05-24 ConcieValve LLC Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
JP2018523684A (ja) * 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
EP3515950A4 (en) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Ltd peptídeo
WO2018200489A1 (en) 2017-04-25 2018-11-01 The Brigham And Women’S Hospital, Inc. Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis
CN107090474A (zh) * 2017-05-22 2017-08-25 山东大学 一种腹主动脉瘤疾病动物模型的制备方法
CN109963877B (zh) * 2017-06-14 2023-01-20 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
RU2020132463A (ru) * 2018-03-06 2022-04-06 Санофи Байотекнолоджи Применение ингибитора pcsk9 для снижения сердечно-сосудистого риска
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
MX2022005959A (es) * 2019-11-18 2022-08-22 Ad Pharmaceuticals Co Ltd Anticuerpo anti-pcsk9 y uso del mismo.
WO2021119321A1 (en) * 2019-12-10 2021-06-17 Regeneron Pharmaceuticals, Inc. Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
CN114277032A (zh) * 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 一种低密度脂蛋白受体基因突变体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
AU2012210480B2 (en) * 2011-01-28 2017-05-18 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
KR101964031B1 (ko) 2011-09-16 2019-04-02 리제너론 파아마슈티컬스, 인크. 전구단백질 전환효소 서브틸리신 켁신-9 (ＰＣＳＫ9)의 억제제를 투여함으로써 지질단백질(ａ)의 농도를 낮추는 방법
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途

Also Published As

Publication number Publication date
WO2015054619A3 (en) 2015-06-04
JP6994484B2 (ja) 2022-02-04
JP2016538248A (ja) 2016-12-08
MX2022013172A (es) 2022-11-30
US20150140002A1 (en) 2015-05-21
AU2014331754A1 (en) 2016-05-26
TWI669131B (zh) 2019-08-21
TW201605475A (zh) 2016-02-16
AU2020203636A1 (en) 2020-06-25
PL3055333T4 (pl) 2020-07-27
EP3689913B1 (en) 2022-03-23
KR20220048051A (ko) 2022-04-19
KR20160062166A (ko) 2016-06-01
EA201690754A1 (ru) 2016-10-31
EA037526B1 (ru) 2021-04-08
JP2019214594A (ja) 2019-12-19
AU2020203636B2 (en) 2023-05-18
ES2914978T3 (es) 2022-06-20
IL244995A0 (en) 2016-05-31
PL3055333T3 (pl) 2020-06-01
WO2015054619A8 (en) 2016-03-31
CA2926942A1 (en) 2015-04-16
EP3055333A2 (en) 2016-08-17
JP6846931B2 (ja) 2021-03-24
MX2020004023A (es) 2020-08-13
IL244995B (en) 2019-12-31
AU2014331754B2 (en) 2020-06-18
CN105814085A (zh) 2016-07-27
CN115154599A (zh) 2022-10-11
PL3689913T3 (pl) 2022-07-04
CN115192704A (zh) 2022-10-18
WO2015054619A2 (en) 2015-04-16
EP3689913A1 (en) 2020-08-05
EP3055333B1 (en) 2019-12-04
KR20230119045A (ko) 2023-08-14

Similar Documents

Publication Publication Date Title
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
PH12016502355A1 (en) Pharmaceutical composition
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EA201991484A1 (ru) Лекарственные формы энзалутамида
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
IN2015DN00450A (es)
PH12016502352A1 (en) Pharmaceutical composition
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
PH12016502353A1 (en) Pharmaceutical composition
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы
UA88769U (uk) Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності

Legal Events

Date Code Title Description
FG Grant or registration